Thursday, 7 July 2016

Age Related Macular Degeneration - Pipeline Review, H1 2016 illuminated by new report

Age Related Macular Degeneration - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Age Related Macular Degeneration pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.
The report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Companies Mentioned
AC Immune SA Achillion Pharmaceuticals, Inc. Aciont Inc. AdAlta Pty Ltd. Adverum Biotechnologies, Inc. Aerie Pharmaceuticals, Inc. Aerpio Therapeutics, Inc. Alimera Sciences, Inc. Alkeus Pharmaceuticals, Inc. Allergan Plc Allinky Biopharma Alteogen Inc. Amakem NV Amarna Therapeutics B.V. Ampio Pharmaceuticals, Inc. Amyndas Pharmaceuticals LLC Apellis Pharmaceuticals, Inc. Apexigen, Inc. Applied Genetic Technologies Corporation Astellas Pharma Inc. Benitec Biopharma Limited BIOCAD Biokine Therapeutics Ltd. BioMAS Ltd. Biomics Biotechnologies Co., Ltd. Biophytis SAS Boehringer Ingelheim GmbH Caladrius Biosciences, Inc. Catalyst Biosciences, Inc. Cell Cure Neurosciences, Ltd. Charlesson LLC. Cipla Ltd. Clanotech AB Clearside BioMedical, Inc. Clonz Biotech Private Limited Coherus BioSciences, Inc. Colby Pharmaceutical Company Crinetics Pharmaceuticals, Inc. Critical Pharmaceuticals Limited Daiichi Sankyo Company, Limited Delenex Therapeutics AG Diffusion Pharmaceuticals Inc. Digna Biotech, S.L. Eleven Biotherapeutics Inc. Elsalys Biotech SAS Exonate Limited F. Hoffmann-La Roche Ltd. Foamix Pharmaceuticals Ltd. Formycon AG Gene Techno Science Co., Ltd. Genentech, Inc. GenSight Biologics S.A. GlaxoSmithKline Plc Grupo Ferrer Internacional, S.A. GTx, Inc. HanAll Biopharma Co., Ltd. Huabo Biopharm Co., Ltd. iCo Therapeutics Inc. Icon Bioscience, Inc. Iconic Therapeutics, Inc. Innovent Biologics, Inc. Intellect Neurosciences, Inc. International Stem Cell Corporation Ionis Pharmaceuticals, Inc. Jeil Pharmaceutical Co., Ltd. Johnson & Johnson Kadmon Corporation, LLC Kala Pharmaceuticals, Inc. Kodiak Sciences, Inc. LeadArtis S.L. M's Science Corporation Mabion SA MacuCLEAR, Inc. Mitotech S.A. Mitsubishi Tanabe Pharma Corporation Navigen Pharmaceuticals, Inc. Navya Biologicals Pvt Ltd Neovacs SA Neumedicines Inc. Neuroptis Biotech Neurotech Pharmaceuticals, Inc. Novartis AG Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. Omeros Corporation Ophthotech Corp. Orphagen Pharmaceuticals, Inc. Oxford BioMedica Plc PanOptica, Inc. Pfenex Inc. Pfizer Inc. Precision Ocular Ltd Promedior, Inc. pSivida Corp. QLT Inc. Quark Pharmaceuticals, Inc. Ra Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. RegenxBio Inc. Ribomic Inc. RXi Pharmaceuticals Corporation SanBio, Inc. Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. SciFluor Life Sciences, LLC Sirnaomics, Inc. Stealth BioTherapeutics Inc. Sucampo Pharmaceuticals, Inc. Sumitomo Dainippon Pharma Co., Ltd. Sun Pharma Advanced Research Company Ltd. TRACON Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. Tyrogenex, Inc. VasGene Therapeutics, Inc. Wellstat Ophthalmics Corporation Xbrane Biopharma AB
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home